Nov 10, 2022Targeted Oncology First Patient With VEGFRi-Associated Hand-Foot Skin Reaction Enrolled in NOVA-IIJordyn Sava November 10, 2022 Part 2 of the NOVA-II phase 2 trial evaluating OQL011 has enrolled the first patient with cancer with...
Nov 9, 2022Clinical Trials Arena I OnQuality enrols first subject in Phase II HFSR therapy trialNovember 9, 2022 The key objectives include the assessment of the efficacy and safety of OQL011 and the identification of an optimal...
Aug 3, 2022Behind Biotech I Hong Tang on Traditional Chinese Medicine and Targeted Cancer Supportive TherapyHosted by Jingyi Liu August 3, 2022 Hong Tang Biography Dr. Hong Tang is Chief Medical Officer, and co-founder of OnQuality...
Jun 30, 2022Hopkins Biotech Podcast I Hong Tang: Targeting the Common Side Effects of Cancer TherapiesHosted by Joe Varriale June 30, 2022 Hong Tang is the co-founder and Chief Medical Officer of OnQuality Pharmaceuticals, a targeted...
Jun 15, 2022Fierce Biotech I After 3 years away, BIO marked by first-time handshakes Written by Max Bayer June 15, 2022 Six days after the World Health Organization officially declared COVID-19 a global pandemic on March...
Jun 1, 2022BioSpectrum Asia I Our approach to managing the side effects of cancer therapy has evolvedSource: https://www.biospectrumasia.com/e-magazine By Dr. Manbeena Chawla June 2022 Although there has been tremendous progress in...